Roche received European Commission (EC) approval for the company’s Tecentriq drug in combination with Avastin and chemo as an initial treatment for people with a specific type of lung cancer.
Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.
FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy for initial treatment of metastatic non-squamous non-small cell lung cancer
Roche announced that the U.S. Food and Drug Administration accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq in combination with Abraxane and carboplatin for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.
Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.
Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.
Merck’s blockbuster anti-PD-1 therapy Keytruda won FDA approval in combination with chemotherapy as a first-line treatment for patients with metastatic squamous non-small cell lung cancer.
Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.
Takeda Pharmaceutical Co.’s lung cancer drug Alunbrig received the recommendation of a European Union panel, more than a year after winning U.S. regulatory approval.
Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.